CYP3A4 and inflammatory breast carcinoma: A previous study by Petros et al also examined a large panel of DME variants, including both phase I and phase II enzymes, as well as drug levels, in 85 metastatic and inflammatory breast cancer patients treated with high-dose cyclophosphamide, cisplatin and carmustine [7], and similarly found that patients with a CYP3A4*1B or CYP3A5*1 variant alleles had higher parent cyclophosphamide levels and significantly worse OS compared to those without the variant (P = 0.043), while those with the GSTM1null genotype did significantly better (P = 0.041).